Abstract
Most of the scientific community and the public recognize the importance of steroidal contraception and the improvements which have been made in their formulation. There is evidence that reduced dosage has been associated with a reduction of side-effects, including those of a more serious nature. At the same time, the prohibitive cost of new drug development, in time, manpower and economic terms, makes it essential to extract the maximum value from those steroids currently in use. Thus the search continues to produce a formulation which maintains efficacy and cycle control and which provides the least disruption of normal metabolic processes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arnt, I. C., Ferrari, A., Sartoretto, J. N and Woutersz, T.D. (1977). Fertil. Steril, 28,549
Schneider, W. H. P., Spona, J., Schmid, R. and Lachnit-Fiason, U. (1977). In Haspels, A. A. and Kay, C. R..(eds.), International Symposium on Hormonal Contraception. ( Amsterdam: Excerpta Medica )
Zador. G. (1979). Acta Obstel Gynecrol. Scand Suppl., 88, 43
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 MTP Press Limited
About this chapter
Cite this chapter
Plunkett, E.R., Allen, H.H., Percival-Smith, R. (1980). Canadian experience with two triphasic oral contraceptive formulations. In: Cortés-Prieto, J., Campos-da-Paz, A., Greenblatt, R.B. (eds) The Development of a New Triphasic Oral Contraceptive. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-6666-9_8
Download citation
DOI: https://doi.org/10.1007/978-94-011-6666-9_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-011-6668-3
Online ISBN: 978-94-011-6666-9
eBook Packages: Springer Book Archive